We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
+31.06%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.93B
AUM Growth
+$243M
(+5.2%)
Cap. Flow
-$263M
Cap. Flow
% of AUM
-5.34%
Top 10 Holdings %
Top 10 Hldgs %
50.68%
Holding
90
New
9
Increased
18
Reduced
10
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$113M |
| 2 |
Acrivon Therapeutics
ACRV
|
+$61.1M |
| 3 |
Vor Biopharma
VOR
|
+$57.5M |
| 4 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$53.5M |
| 5 |
Vaxcyte
PCVX
|
+$50.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$180M |
| 2 |
Biogen
BIIB
|
+$114M |
| 3 |
Relmada Therapeutics
RLMD
|
+$74M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$70.9M |
| 5 |
THRD
Third Harmonic Bio
THRD
|
+$49.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.49% |
| 2 | Financials | 0.51% |
| 3 | Miscellaneous | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Acrivon Therapeutics
ACRV
$78.4M
| $55.4M | 1.12% |
+4,810,508
| New | +$61.1M |
|
27
Tyra Biosciences
TYRA
$1.52B
| $55M | 1.12% |
7,236,454
| – | – |
|
28
Acumen Pharmaceuticals
ABOS
$209M
| $52.8M | 1.07% |
9,770,773
| – | – |
|
|
AKRO
29
DELISTED
Akero Therapeutics
AKRO
| $52.6M | 1.07% |
958,980
| – | – |
|
|
CLYM
30
Climb Bio
CLYM
$799M
| $48.3M | 0.98% |
13,150,849
| – | – |
|
31
GH Research
GHRS
$1.89B
| $47.6M | 0.97% |
4,898,373
| – | – |
|
|
ICVX
32
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $47.4M | 0.96% |
5,963,565
| – | – |
|
33
Rocket Pharmaceuticals
RCKT
$374M
| $47.1M | 0.96% |
2,407,149
+300,000
| +14% | +$5.52M |
|
34
Nkarta
NKTX
$206M
| $46.8M | 0.95% |
7,805,129
| – | – |
|
35
NewAmsterdam Pharma
NAMS
$2.53B
| $43.6M | 0.88% |
+4,000,000
| New | +$39.8M |
|
36
RxSight
RXST
$234M
| $38.7M | 0.78% |
3,052,796
| – | – |
|
37
AN2 Therapeutics
ANTX
$202M
| $36M | 0.73% |
3,773,517
| – | – |
|
|
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
| $32.3M | 0.66% |
4,397,368
+40,736
| +0.9% | +$260K |
|
39
Geron
GERN
$842M
| $31.3M | 0.63% |
12,930,711
-17,195,588
| -57% | -$38.5M |
|
40
Design Therapeutics
DSGN
$765M
| $30.5M | 0.62% |
2,971,231
+198,000
| +7% | +$2.68M |
|
|
HLVX
41
DELISTED
HilleVax
HLVX
| $29.4M | 0.6% |
1,760,019
| – | – |
|
|
KNTE
42
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $26M | 0.53% |
4,264,144
| – | – |
|
43
Viridian Therapeutics
VRDN
$2.47B
| $25.7M | 0.52% |
880,000
| – | – |
|
44
ARS Pharmaceuticals
SPRY
$423M
| $25.7M | 0.52% |
+3,009,678
| New | +$19.5M |
|
45
Celcuity
CELC
$4.05B
| $19.6M | 0.4% |
+1,400,001
| New | +$14.3M |
|
46
Solid Biosciences
SLDB
$897M
| $18.4M | 0.37% |
3,426,286
+2,601,761
| +316% | +$17.1M |
|
|
DALS
47
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15M | 0.3% |
1,500,000
| – | – |
|
|
SCPH
48
DELISTED
scPharmaceuticals
SCPH
| $13.3M | 0.27% |
+1,856,904
| New | +$11.3M |
|
49
Enliven Therapeutics
ELVN
$3.91B
| $13.3M | 0.27% |
+812,681
| New | +$13M |
|
50
Tenaya Therapeutics
TNYA
$150M
| $12.2M | 0.25% |
6,067,483
+4,465,474
| +279% | +$10.9M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, RA Capital Management held 90 positions worth $4.93B, up 5.2% from $4.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
RA Capital Management withdrew a net $263M in Q4 2022, closing 20 positions and reducing 10 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $180M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.
Against the trend, RA Capital Management opened a new position in Inhibrx, Inc. Common Stock worth $95M.
- RA Capital Management's largest Q4 2022 buy was Inhibrx, Inc. Common Stock: 3,853,867 shares worth $95M.
- RA Capital Management added most to Vor Biopharma in Q4 2022, an estimated $57.5M increase.
- RA Capital Management's biggest Q4 2022 reduction was Biogen, cutting an estimated $114M.
- RA Capital Management fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $180M.
- RA Capital Management's ten largest holdings make up 51% of its $4.93B portfolio in Q4 2022.
- RA Capital Management opened 9 new positions and closed 20 in Q4 2022.
- RA Capital Management's portfolio value rose 5.2% quarter-over-quarter to $4.93B.
Based on RA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.